Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 45

Results For "pharmaceuticals"

1579 News Found

FDA lifts hold on Rocket Pharma's gene therapy trial
News | August 22, 2025

FDA lifts hold on Rocket Pharma's gene therapy trial

Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort


NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
News | August 21, 2025

NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity

NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity


Alembic receives USFDA final approval for Macitentan Tablets, 10 mg
News | August 19, 2025

Alembic receives USFDA final approval for Macitentan Tablets, 10 mg

Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension


Sarepta advances siRNA collaboration and sale of arrowhead equity investment
News | August 19, 2025

Sarepta advances siRNA collaboration and sale of arrowhead equity investment

Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation


From Policy to Practice: How India’s Pharmaceutical Industry is Being Shaped by the PLI Scheme – by Vikram Aditya Sehgal, Director – Finance, Centrient India
Opinion | August 18, 2025

From Policy to Practice: How India’s Pharmaceutical Industry is Being Shaped by the PLI Scheme – by Vikram Aditya Sehgal, Director – Finance, Centrient India

The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations


Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico
News | August 18, 2025

Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico

The projected business potential is around US$ 1 million in the first year


Cohance Lifesciences reports 13% revenue growth in Q1 FY26
News | August 16, 2025

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site


AbbVie to invest $195 million to expand API manufacturing in North Chicago
News | August 16, 2025

AbbVie to invest $195 million to expand API manufacturing in North Chicago

The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines